BSF Enterprise PLC (BSFA) AI Stock Analysis

• Market Cap: £2.94M
• Dividend Yield: N/A
• Average Volume (3M): 609.25K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: 346.77%
• EPS Growth: -2.53%
• Country: UK
• Employees: 15
• Sector: Healthcare
• Sector Strength: 58
• Industry: Asset Management
• EPS (TTM): -0.02
• Shares Outstanding: 123,648,440
• 10 Day Avg. Volume: 255,852
• 30 Day Avg. Volume: 609,245
• PEG Ratio: 0.18
• Price to Book (P/B): 0.49
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.16
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: 2.50p ▲(5.04%Upside)

The company's overall score is primarily driven by its positive corporate events and short-term technical momentum, which are offset by significant operational losses and a challenging valuation due to negative profitability metrics.

BSF Enterprise PLC Business Overview & Revenue Model

Company Description

BSF Enterprise Plc does not have significant operations. It intends to acquire the companies or businesses within marketing and technology sectors. The company was incorporated in 2018 and is based in London, United Kingdom.

How the Company Makes Money

BSF Enterprise PLC generates revenue through the commercialization of its proprietary tissue engineering technologies and biomaterials. The company earns money by licensing its technologies to pharmaceutical and biotechnology companies, as well as through direct sales of its lab-grown tissues and biomaterials to research institutions and industrial clients. Strategic partnerships with leading companies in the healthcare and biotechnology sectors also play a significant role in supporting its earnings. Additionally, BSF Enterprise may receive grants and funding from governmental and non-governmental organizations to support its research and development efforts.

BSF Enterprise PLC Financial Statement Overview

Summary

The company exhibits revenue growth, but significant losses at the operational level and negative cash flows highlight financial challenges. A strong equity position offers some stability, though declining over time.

Income Statement

The company has shown a significant increase in revenue from previous years, indicating growth. However, the gross profit is negative, with substantial losses at the EBIT and net income levels, reflecting continued operational challenges and unprofitability.

Balance Sheet

The company maintains a strong equity position with a high equity ratio, indicating financial stability. However, the presence of debt and declining stockholders' equity over the years are potential risks.

Cash Flow

The cash flow statement reveals negative operating cash flow, which is concerning. Free cash flow remains negative, though capital expenditures are minimal. The company's operating activities are not generating sufficient cash to cover its losses.

Breakdown
TTM	Sep 2024	Sep 2023	Sep 2022	Sep 2021	Sep 2020
Income Statement		Total Revenue
67.24K	57.82K	12.94K	0.00	0.00	0.00
	Gross Profit
-105.91K	-26.64K	-86.55K	-160.50K	0.00	0.00
	EBIT
-1.79M	-1.79M	-1.57M	-927.32K	-58.22K	-93.76K
	EBITDA
-1.71M	-1.68M	-1.46M	-905.76K	-58.22K	0.00
	Net Income Common Stockholders
-1.71M	-1.67M	-1.50M	-930.04K	-58.43K	-93.93K
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
1.37M	637.66K	2.32M	1.06M	359.87K	445.06K
	Total Assets
4.30M	3.50M	5.26M	4.03M	401.45K	455.40K
	Total Debt
118.00K	78.05K	156.93K	231.88K	0.00	0.00
	Net Debt
-1.26M	-559.61K	-2.16M	-829.65K	-359.87K	-445.06K
	Total Liabilities
307.14K	305.07K	401.63K	449.47K	36.63K	32.26K
	Stockholders Equity
3.99M	3.19M	4.86M	3.58M	364.82K	423.14K
Cash Flow		Free Cash Flow
-1.79M	-1.60M	-1.44M	-677.86K	-85.19K	-107.14K
	Operating Cash Flow
-1.78M	-1.59M	-1.38M	-667.24K	-85.19K	-107.14K
	Investing Cash Flow
-9.68K	-12.02K	-64.85K	1.75K	0.00	0.00
	Financing Cash Flow
2.81M	-78.88K	2.70M	1.37M	0.00	0.00

BSF Enterprise PLC Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.38
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BSFA, the sentiment is Positive. The current price of 2.38 is above the 20-day moving average (MA) of 2.24, above the 50-day MA of 2.16, and below the 200-day MA of 2.77, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 53.70 is Neutral, neither overbought nor oversold. The STOCH value of 50.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:BSFA.

BSF Enterprise PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BSFA	57 Neutral	£2.94M	―	-41.55%	―	346.77%	-2.53%
Sector *	54 Neutral	$5.37B	3.26	-45.10%	3.30%	16.81%	0.02%
BLU		£4.56M	―	-143.36%	―	―	―
GUN	47 Neutral	£994.61K	―	-34.06%	―	―	80.00%
BRH	43 Neutral	£1.84M	―	-97.45%	―	502.47%	-501.58%
PRIM		£4.89M	1.82	48.96%	―	―	―
CHP	44 Neutral	£2.90M	―	-71.01%	―	―	―

BSF Enterprise PLC Corporate Events

BSF Enterprise PLC Amends Warrant Terms to Boost Investment Appeal

BSF Enterprise PLC has announced an amendment to its warrant instrument, originally issued on 26 April 2022. The exercise price for the warrants has been reduced from 15p to 7.5p, and the exercise term has been extended by two years, now expiring on 17 May 2027. This adjustment aims to enhance the attractiveness of the warrants, potentially increasing stakeholder engagement and investment in the company’s innovative tissue-engineered materials.

BSF Enterprise’s Lab-Grown Leather Ltd Makes Breakthroughs in Sustainable Leather

BSF Enterprise PLC’s subsidiary, Lab-Grown Leather Ltd (LGL), has announced significant advancements in its lab-grown leather products, specifically with its Elemental+™ and Elemental X™ lines. Elemental+™ offers ultra-thin and strong leather, ideal for industries where weight is critical, while Elemental X™ includes the innovative T-Rex leather, derived from synthetic T-Rex DNA, which has attracted global media attention and new commercial partnerships. These developments position LGL as a leader in sustainable leather alternatives, with implications for luxury goods, aerospace, and automotive markets.

BSF Enterprise PLC Secures Strategic Investment to Drive Growth

BSF Enterprise PLC has announced a strategic investment through the conditional placement of 4,725,000 new ordinary shares, raising £141,750 to support its strategic business and growth plans. This move, backed by the company’s largest shareholder, is expected to create significant value inflection points throughout 2025, with the shares anticipated to be listed on the London Stock Exchange by mid-May.

BSF Enterprise PLC Advances Lab-Grown Leather with T-Rex Innovation

BSF Enterprise PLC’s subsidiary, Lab-Grown Leather Ltd, is advancing its lab-grown leather technology towards commercialization with the introduction of Elemental X™, a luxury material developed using their proprietary Advanced Tissue Engineering Platform. In collaboration with VML and The Organoid Company, they are pioneering the creation of T-Rex leather, a sustainable and cruelty-free alternative inspired by the DNA of the extinct Tyrannosaurus rex. This innovative venture aims to revolutionize the luxury materials industry by providing eco-friendly and ethically sound products, with initial applications in fashion and potential expansion into other sectors.